|
PSA
2.6 – 4.0 ng/ml
|
|
Gleason Score
|
Pathology Risk
|
Clinical
Stage
|
|
T1c
|
T2a
|
T2b
|
T2c
|
|
2-4
|
Confined
to Prostate
|
92
|
82-98
|
85
|
69-96
|
80
|
61-95
|
78
|
58-94
|
|
Spread to Prostate Capsule
|
8
|
2-18
|
15
|
4-31
|
20
|
5-39
|
22
|
6-42
|
|
Spread to Seminal Vesicles
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
|
Spread to Lymph Nodes
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
|
5-6
|
Confined
to Prostate
|
84
|
81-86
|
71
|
66-75
|
63
|
57-59
|
61
|
50-70
|
| |
Spread to Prostate Capsule
|
15
|
13-18
|
27
|
23-31
|
34
|
28-40
|
36
|
27-45
|
| |
Spread to Seminal Vesicles
|
1
|
0-1
|
2
|
1-3
|
2
|
1-4
|
2
|
1-5
|
| |
Spread to Lymph Nodes
|
0
|
0-0
|
0
|
0-1
|
1
|
0-2
|
1
|
0-4
|
|
3+4=7
|
Confined
to Prostate
|
68
|
62-74
|
50
|
43-57
|
41
|
33-48
|
38
|
27-50
|
|
Spread to Prostate Capsule
|
27
|
22-33
|
41
|
35-48
|
47
|
40-55
|
48
|
37-59
|
|
Spread to Seminal Vesicles
|
4
|
2-7
|
7
|
3-12
|
9
|
4-15
|
8
|
2-17
|
|
Spread to Lymph Nodes
|
1
|
0-2
|
2
|
0-4
|
3
|
0-8
|
5
|
0-15
|
|
4+3=7
|
Confined
to Prostate
|
58
|
48-67
|
39
|
30-48
|
30
|
22-39
|
27
|
18-40
|
| |
Spread to Prostate Capsule
|
37
|
29-46
|
52
|
43-61
|
57
|
47-67
|
57
|
44-70
|
| |
Spread to Seminal Vesicles
|
4
|
1-7
|
6
|
2-12
|
7
|
3-14
|
6
|
2-16
|
| |
Spread to Lymph Nodes
|
1
|
0-3
|
2
|
0-6
|
4
|
0-12
|
7
|
0-21
|
|
8-10
|
Confined
to Prostate
|
52
|
41-63
|
33
|
24-44
|
25
|
17-34
|
23
|
14-34
|
|
Spread to Prostate Capsule
|
40
|
31-50
|
53
|
44-63
|
57
|
46-68
|
57
|
44-70
|
|
Spread to Seminal Vesicles
|
6
|
3-12
|
10
|
4-18
|
12
|
5-22
|
10
|
3-22
|
|
Spread to Lymph Nodes
|
1
|
0-4
|
3
|
0-8
|
5
|
0-14
|
8
|
0-22
|
